News|Videos|November 17, 2026

A Couple Faces Bladder Cancer Together, With a Nurse as Care Partner

Author(s)Alex Biese
Fact checked by: Kaitlyn M. Le

A registered nurse and breast cancer survivor, JoAnne Page became her husband Ray's care partner when his cancer stopped responding to treatment.

Ray Page went to his urologist thinking an aging prostate explained why he was urinating so often. Instead, a scope found a small tumor at the top of his bladder and a larger one near his prostate. "I could have felt the blood drain out of my head," Ray says. "And I was shocked. I was like, 'No, it can't be. Why me?'"

Ray was diagnosed with non-muscle invasive bladder cancer in 2025. For his wife of 35 years, JoAnne, a registered nurse with an oncology background and a breast cancer survivor herself, the news meant their family would face cancer again. In November, which is both National Family Caregivers Month and Bladder Health Month, the couple spoke with CURE about what that experience has taught them.

When treatment stopped working

Ray's first treatment was BCG, a weakened form of bacteria placed into the bladder. BCG fails in up to 40% of people with non-muscle invasive bladder cancer, according to a medical review published in the journal Bladder Cancer. JoAnne says Ray's body reacted strongly to it, leaving him in bed for long stretches. "He hardly ate. He got so tired," she says. "I was in no way prepared for that."

Surgery to remove part of his bladder took out five tumors, but the cancer came back, and removing the whole bladder became a possibility. "I thought they got it all," Ray says.

Researching options as a team

Ray, who built homes for a living, says he was used to being in charge. "I have to stay in my lane. This is out of my league," he recalls thinking. "And I leaned on JoAnne very heavily." The couple researched treatments together, which JoAnne says helped them know which questions to ask his care team.

In January 2026, Ray began Inlexzo (gemcitabine intravesical system), which the Food and Drug Administration approved in September 2025 for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. A small device placed into the bladder through a catheter slowly releases the chemotherapy gemcitabine over three weeks before it is removed. In the trial that supported the approval, 82% of 83 patients had no signs of cancer after treatment, and 51% of those patients stayed that way for at least a year, according to the FDA. The most common side effects included needing to urinate often, urinary tract infections and pain when urinating, according to the drug's prescribing information.

Because the device is swapped every three weeks, Ray says, his bladder was checked that often, too. "It was a no-brainer," he says. Ray was the first patient at his practice to receive the treatment, so he kept a list of questions in his phone for each visit. Other patients have also shared their experience with Inlexzo with CURE.

Caring for the caregiver

As a nurse, JoAnne often reminds caregivers that someone needs to look after them, too. "I always, always tell the caregivers, 'You're the one I worry about,'" she says.

Ray says he has had no new tumors since starting treatment. "It's strengthened us. It's given us a lot of hope," he says. "We're able to make plans."

Questions to ask your care team

Is my cancer considered BCG-unresponsive?

What are my options besides removing my bladder?

Which urinary symptoms or signs of infection should we call about?

What support is available for my care partner?

For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.



Related to this article